NFXF Blog
Featured
Fragile X has once again been included in the FY26 Peer-Reviewed Medical Research Program (PRMRP) authorized topic list. This continued inclusion ensures that researchers can apply for Department of War awards supporting innovative, high-impact Fragile X research of clear scientific merit.
‘Fishing for a Cureʼ Reels in Over $20,000 This Year!
12 mins read
FORE! Fragile X Annual Golf Event Raises over $63,000 (So Far!)
05 mins read
Research Funding Opportunities from CDMRP/PRMRP for Fiscal Year 2026
03 mins read
Update from Shionogi on EXPERIENCE Fragile X Clinical Trial
04 mins read
All Articles
[This is an archived page referring to the Seaside Arbaclofen (STX209) clinical trial, which was terminated in 2013.] We have experienced a setback with the cancellation of the extension phase of the STX209 drug trials for Fragile X syndrome, and what have been deemed the technical failures of two other ongoing trials of this drug.
[This is an archived page referring to the Seaside Arbaclofen (STX209) clinical trial, which was terminated in 2013.] By now, many of you have heard that Seaside Therapeutics has decided to end the extension of the trial medication Arbaclofen (STX209).